Senseonics: Eversense 365 Receives FDA Clearance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St recovers as yields ease; Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
BTIG Reiterates Neutral Rating on Senseonics Holdings (SENS)
September 17, 2024 8:35 AM EDTBTIG analyst Marie Thibault reiterated a Neutral rating on Senseonics Holdings (NYSE: SENS).
The analyst comments "This morning, Senseonics announced that they received FDA clearance for the 365-day Eversense continuous glucose monitoring (CGM) system. The 365-day system is indicated for adults with Type 1 and Type 2 diabetes and... More
Stifel Reiterates Buy Rating on Senseonics Holdings (SENS)
September 17, 2024 8:29 AM EDTStifel analyst Mathew Blackman reiterated a Buy rating and $2.50 price target on Senseonics Holdings (NYSE: SENS).
The analyst comments "This morning, SENS announced on-time FDA approval of Eversense 365-day with iCGM status; a 4Q24 US launch timeline was also re-affirmed. Importantly, approval... More
